Retatrutide

Pack of 10 × 100mg powder vials in a protective case

Enlarge

Choose strength

5mg × 10 vials 10mg × 10 vials 15mg × 10 vials 20mg × 10 vials 30mg × 10 vials 40mg × 10 vials 50mg × 10 vials 60mg × 10 vials 100mg × 10 vials

Price · per pack

£1215.00

Available to order

£1705.00 Save £490.00 (29%)

£121.50 per vial · 10 vials per case

Free delivery £50+ Royal Mail Tracked 24

Approx. 2-week lead time. Dispatch follows availability.

Batch documentation

COA not yet available. Ask about documentation →

Explore research & studies

Product overview & specifications

Retatrutide in 10-vial case. Check the product record for the stated strength, storage information and batch-document availability.

Strength: 100mg × 10 vials
Presentation: 10-vial case
Batch documentation: availability shown on this listing

Strength100mg × 10 vials

Presentation10-vial case

Purity99%+

Storage2-8 C

Part number: RT100-10PK
Storage: Store refrigerated at 2-8 C, protected from light.
COA: Added to your account when available
Delivery: Royal Mail Tracked 24 is £4.95, or free on merchandise subtotals of £50+; Approx. 2-week lead time
Tracking: Emailed once dispatched and shown in your profile
Contents: 10-vial case
Status: Research use only

For laboratory research only

For laboratory research use only. Not for human or veterinary use. No use instructions or medical guidance is provided. Understand COA documentation.

Research information

Retatrutide research profile

What is being studied?

Retatrutide (LY3437943) is an engineered single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. This three-receptor profile makes it a reference compound for multi-agonist receptor pharmacology.

Structural and signalling studies have examined how retatrutide is recognised by GIPR, GLP-1R and GCGR in receptor-Gs complexes. Laboratory applications include receptor binding, cAMP-response and pathway-bias comparisons; results must be interpreted within the tested model.

Research areas

Comparative GIPR, GLP-1R and GCGR binding and activation assays
cAMP and Gs-coupled signalling measurements
Structural comparison of single-, dual- and triple-agonist peptide designs

Selected studies

Structural and cell study · 2024
Structural insights into retatrutide triple agonism ↗
Examined retatrutide recognition by three receptor complexes and receptor signalling assays.
Human phase 2 trial · 2023
Triple-hormone-receptor agonist retatrutide ↗
A randomised trial of investigational retatrutide in adults with obesity; it did not test this catalogue product.

How to read this research

These papers study defined compounds in specific experimental systems or clinical trials. They do not test or certify this product, its batch or its prepared presentation. Component and related-peptide studies do not establish the effects of a finished blend. Findings are research context, not evidence of safety or suitability for personal use. For laboratory research only; no treatment, dosing or use advice is provided.

Technical product record

Retatrutide research record

Molecular identity and stated sequence or composition, alongside the batch, storage, dispatch and document record for this 10-vial case.

Molecular identity

Single-peptide triple receptor agonist

Sequence / composition

Engineered peptide agonist of GIPR, GLP-1R and GCGR

Product record

The listing identifies the presentation, specification, storage record, dispatch status, and batch-document availability for the relevant product or batch.

Use restriction

For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.